Meeting
2020 ASCO Virtual Scientific Program
Longitudinal monitoring by next generation sequencing of plasma cell-free DNA in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with ALK tyrosine kinase inhibitors.
Authors
Minsuk Kwon
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Minsuk Kwon , Bo Mi Ku , Sehhoon Park , Hyun Ae Jung , Jong-Mu Sun , Se-Hoon Lee , Jin Seok Ahn , Keunchil Park , Myung-Ju Ahn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9603)
DOI
10.1200/JCO.2020.38.15_suppl.9603
Abstract #
9603
Poster Bd #
369
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Circulating tumor DNA to investigate resistance mechanism and clone evolution of ALK TKI treated lung adenocarcinoma.
First Author: Gang Hua
Poster
2023 ASCO Annual Meeting
Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC.
First Author: Kaushal Parikh
Poster
2020 ASCO Virtual Scientific Program
Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.
First Author: D. Ross Camidge
Poster
2016 ASCO Annual Meeting
Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1.
First Author: Daniel Shao-Weng Tan